Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Experimental & Translational Stroke Medicine
Published in: Experimental & Translational Stroke Medicine 1/2011

Open Access 01-12-2011 | Research

Early outcome and blood-brain barrier integrity after co-administered thrombolysis and hyperbaric oxygenation in experimental stroke

Authors: Dominik Michalski, Johann Pelz, Christopher Weise, Johannes Kacza, Johannes Boltze, Jens Grosche, Manja Kamprad, Dietmar Schneider, Carsten Hobohm, Wolfgang Härtig

Published in: Experimental & Translational Stroke Medicine | Issue 1/2011

Login to get access

Abstract

Background

After promising results in experimental stroke, normobaric (NBO) or hyperbaric oxygenation (HBO) have recently been discussed as co-medication with tissue plasminogen activator (tPA) for improving outcome. This study assessed the interactions of hyperoxia and tPA, focusing on survival, early functional outcome and blood-brain barrier (BBB) integrity following experimental stroke.

Methods

Rats (n = 109) underwent embolic middle cerebral artery occlusion or sham surgery. Animals were assigned to: Control, NBO (60-minute pure oxygen), HBO (60-minute pure oxygen at 2.4 absolute atmospheres), tPA, or HBO+tPA. Functional impairment was assessed at 4 and 24 hours using Menzies score, followed by intravenous application of FITC-albumin as a BBB permeability marker, which was allowed to circulate for 1 hour. Further, blood sampling was performed at 5 and 25 hours for MMP-2, MMP-9, TIMP-1 and TIMP-2 concentration.

Results

Mortality rates did not differ significantly between groups, whereas functional improvement was found for NBO, tPA and HBO+tPA. NBO and HBO tended to stabilize BBB and to reduce MMP-2. tPA tended to increase BBB permeability with corresponding MMP and TIMP elevation. Co-administered HBO failed to attenuate these early deleterious effects, independent of functional improvement.

Conclusions

The long-term consequences of simultaneously applied tPA and both NBO and HBO need to be addressed by further studies to identify therapeutic potencies in acute stroke, and to avoid unfavorable courses following combined treatment.
Appendix
Available only for authorised users
Literature
1.
Endres M, Engelhardt B, Koistinaho J, Lindvall O, Meairs S, Mohr JP, Planas A, Rothwell N, Schwaninger M, Schwab ME, Vivien D, Wieloch T, Dirnagl U: Improving outcome after stroke: overcoming the translational roadblock. Cerebrovasc Dis 2008, 25: 268–278. 10.1159/000118039PubMedCrossRef
2.
Bechmann I, Galea I, Perry VH: What is the blood-brain barrier (not)? Trends Immunol 2007, 28: 5–11. 10.1016/j.it.2006.11.007PubMedCrossRef
3.
Kaur C, Ling EA: Blood brain barrier in hypoxic-ischemic conditions. Curr Neurovasc Res 2008, 5: 71–81. 10.2174/156720208783565645PubMedCrossRef
4.
5.
Young AR, Ali C, Duretête A, Vivien D: Neuroprotection and stroke: time for a compromise. J Neurochem 2007, 103: 1302–1309. 10.1111/j.1471-4159.2007.04866.xPubMedCrossRef
6.
Li F, Tatlisumak T: Focal brain ischemia models in rodents. In Handbook of Experimental Neurology. Edited by: Tatlisumak T, Fisher M. Cambridge: Cambridge University Press; 2006:212–228.
7.
Belayev L, Busto R, Zhao W, Ginsberg MD: Quantitative evaluation of blood-brain barrier permeability following middle cerebral artery occlusion in rats. Brain Res 1996, 739: 88–96. 10.1016/S0006-8993(96)00815-3PubMedCrossRef
8.
Pillai DR, Dittmar MS, Baldaranov D, Heidemann RM, Henning EC, Schuierer G, Bogdahn U, Schlachetzki F: Cerebral ischemia-reperfusion injury in rats-a 3 T MRI study on biphasic blood-brain barrier opening and the dynamics of edema formation. J Cereb Blood Flow Metab 2009, 29: 1846–1855. 10.1038/jcbfm.2009.106PubMedCentralPubMedCrossRef
9.
Candelario-Jalil E, Yang Y, Rosenberg GA: Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience 2009, 158: 983–994. 10.1016/j.neuroscience.2008.06.025PubMedCentralPubMedCrossRef
10.
Rosell A, Lo EH: Multiphasic roles for matrix metalloproteinases after stroke. Curr Opin Pharmacol 2008, 8: 82–89. 10.1016/j.coph.2007.12.001PubMedCrossRef
11.
Schäbitz WR, Schade H, Heiland S, Kollmar R, Bardutzky J, Henninger N, Müller H, Carl U, Toyokuni S, Sommer C, Schwab S: Neuroprotection by hyperbaric oxygenation after experimental focal cerebral ischemia monitored by MRI. Stroke 2004, 35: 1175–1179. 10.1161/01.STR.0000125868.86298.8ePubMedCrossRef
12.
Liu W, Hendren J, Qin XJ, Liu KJ: Normobaric hyperoxia reduces the neurovascular complications associated with delayed tissue plasminogen activator treatment in a rat model of focal cerebral ischemia. Stroke 2009, 40: 2526–2531. 10.1161/STROKEAHA.108.545483PubMedCentralPubMedCrossRef
13.
Sun L, Zhou W, Mueller C, Sommer C, Heiland S, Bauer AT, Marti HH, Veltkamp R: Oxygen therapy reduces secondary hemorrhage after thrombolysis in thromboembolic cerebral ischemia. J Cereb Blood Flow Metab 2010, 30: 1651–1660. 10.1038/jcbfm.2010.50PubMedCentralPubMedCrossRef
14.
Qin Z, Karabiyikoglu M, Hua Y, Silbergleit R, He Y, Keep RF, Xi G: Hyperbaric oxygen-induced attenuation of hemorrhagic transformation after experimental focal transient cerebral ischemia. Stroke 2007, 38: 1362–1367. 10.1161/01.STR.0000259660.62865.ebPubMedCrossRef
15.
Veltkamp R, Bieber K, Wagner S, Beynon C, Siebing DA, Veltkamp C, Schwaninger M, Marti HH: Hyperbaric oxygen reduces basal lamina degradation after transient focal cerebral ischemia in rats. Brain Res 2006, 1076: 231–237. 10.1016/j.brainres.2006.01.013PubMedCrossRef
16.
Veltkamp R, Siebing DA, Sun L, Heiland S, Bieber K, Marti HH, Nagel S, Schwab S, Schwaninger M: Hyperbaric oxygen reduces blood-brain barrier damage and edema after transient focal cerebral ischemia. Stroke 2005, 36: 1679–1683. 10.1161/01.STR.0000173408.94728.79PubMedCrossRef
17.
Michalski D, Härtig W, Schneider D, Hobohm C: Use of normobaric and hyperbaric oxygen in acute focal cerebral ischemia - a preclinical and clinical review. Acta Neurol Scand 2011, 123: 85–97.PubMedCrossRef
18.
Singhal AB: A review of oxygen therapy in ischemic stroke. Neurol Res 2007, 29: 173–183. 10.1179/016164107X181815PubMedCrossRef
19.
Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D, ECASS Investigators: Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008, 359: 1317–1329. 10.1056/NEJMoa0804656PubMedCrossRef
20.
Burggraf D, Martens HK, Dichgans M, Hamann GF: rt-PA causes a dose-dependent increase in the extravasation of cellular and non-cellular blood elements after focal cerebral ischemia. Brain Res 2007, 1164: 55–62.PubMedCrossRef
21.
Adibhatla RM, Hatcher JF: Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategies. CNS Neurol Disord Drug Targets 2008, 7: 243–253. 10.2174/187152708784936608PubMedCentralPubMedCrossRef
22.
Jin R, Yang G, Li G: Molecular insights and therapeutic targets for blood-brain barrier disruption in ischemic stroke: critical role of matrix metalloproteinases and tissue-type plasminogen activator. Neurobiol Dis 2010, 38: 376–385. 10.1016/j.nbd.2010.03.008PubMedCentralPubMedCrossRef
23.
Michalski D, Küppers-Tiedt L, Weise C, Laignel F, Härtig W, Raviolo M, Schneider D, Hobohm C: Long-term functional and neurological outcome after simultaneous treatment with tissue-plasminogen activator and hyperbaric oxygen in early phase of embolic stroke in rats. Brain Res 2009, 1303: 161–168.PubMedCrossRef
24.
Zhang RL, Chopp M, Zhang ZG, Jiang Q, Ewing JR: A rat model of focal embolic cerebral ischemia. Brain Res 1997, 766: 83–92. 10.1016/S0006-8993(97)00580-5PubMedCrossRef
25.
Menzies SA, Hoff JT, Betz AL: Middle cerebral artery occlusion in rats: a neurological and pathological evaluation of a reproducible model. Neurosurgery 1992, 31: 100–106. 10.1227/00006123-199207000-00014PubMedCrossRef
26.
Michalski D, Grosche J, Pelz J, Schneider D, Weise C, Bauer U, Kacza J, Gärtner U, Hobohm C, Härtig W: A novel quantification of blood-brain barrier damage and histochemical typing after embolic stroke in rats. Brain Res 2010, 1359: 186–200.PubMedCrossRef
27.
Sternberger NH, Sternberger LA: Blood-brain barrier protein recognized by monoclonal antibody. Proc Natl Acad Sci USA 1987, 84: 8169–8173. 10.1073/pnas.84.22.8169PubMedCentralPubMedCrossRef
28.
Fujiwara N, Murata Y, Arai K, Egi Y, Lu J, Wu O, Singhal AB, Lo EH: Combination therapy with normobaric oxygen (NBO) plus thrombolysis in experimental ischemic stroke. BMC Neurosci 2009, 10: 79. 10.1186/1471-2202-10-79PubMedCentralPubMedCrossRef
29.
Henninger N, Bratane BT, Bastan B, Bouley J, Fisher M: Normobaric hyperoxia and delayed tPA treatment in a rat embolic stroke model. J Cereb Blood Flow Metab 2009, 29: 119–129. 10.1038/jcbfm.2008.104PubMedCrossRef
30.
Gasche Y, Fujimura M, Morita-Fujimura Y, Copin JC, Kawase M, Massengale J, Chan PH: Early appearance of activated matrix metalloproteinase-9 after focal cerebral ischemia in mice: a possible role in blood-brain barrier dysfunction. J Cereb Blood Flow Metab 1999, 19: 1020–1028.PubMedCrossRef
31.
Strbian D, Durukan A, Pitkonen M, Marinkovic I, Tatlisumak E, Pedrono E, Abo-Ramadan U, Tatlisumak T: The blood-brain barrier is continuously open for several weeks following transient focal cerebral ischemia. Neuroscience 2008, 153: 175–181. 10.1016/j.neuroscience.2008.02.012PubMedCrossRef
32.
Chen B, Friedman B, Cheng Q, Tsai P, Schim E, Kleinfeld D, Lyden PD: Severe blood-brain barrier disruption and surrounding tissue injury. Stroke 2009, 40: e666-e674. 10.1161/STROKEAHA.109.551341PubMedCentralPubMedCrossRef
33.
Abo-Ramadan U, Durukan A, Pitkonen M, Marinkovic I, Tatlisumak E, Pedrono E, Soinne L, Strbian D, Tatlisumak T: Post-ischemic leakiness of the blood-brain barrier: a quantitative and systematic assessment by Patlak plots. Exp Neurol 2009, 219: 328–333. 10.1016/j.expneurol.2009.06.002PubMedCrossRef
34.
Kelly MA, Shuaib A, Todd KG: Matrix metalloproteinase activation and blood-brain barrier breakdown following thrombolysis. Exp Neurol 2006, 200: 38–49. 10.1016/j.expneurol.2006.01.032PubMedCrossRef
35.
Park KP, Rosell A, Foerch C, Xing C, Kim WJ, Lee S, Opdenakker G, Furie KL, Lo EH: Plasma and brain matrix metalloproteinase-9 after acute focal cerebral ischemia in rats. Stroke 2009, 40: 2836–2842. 10.1161/STROKEAHA.109.554824PubMedCentralPubMedCrossRef
36.
Fukuda S, Fini CA, Mabuchi T, Koziol JA, Eggleston LL Jr, del Zoppo GJ: Focal cerebral ischemia induces active proteases that degrade microvascular matrix. Stroke 2004, 35: 998–1004. 10.1161/01.STR.0000119383.76447.05PubMedCentralPubMedCrossRef
37.
Bauer AT, Bürgers HF, Rabie T, Marti HH: Matrix metalloproteinase-9 mediates hypoxia-induced vascular leakage in the brain via tight junction rearrangement. J Cereb Blood Flow Metab 2010, 30: 837–848. 10.1038/jcbfm.2009.248PubMedCentralPubMedCrossRef
38.
Heo JH, Lucero J, Abumiya T, Koziol JA, Copeland BR, del Zoppo GJ: Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J Cereb Blood Flow Metab 1999, 19: 624–633.PubMedCrossRef
39.
Tsuji K, Aoki T, Tejima E, Arai K, Lee SR, Atochin DN, Huang PL, Wang X, Montaner J, Lo EH: Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia. Stroke 2005, 36: 1954–1959. 10.1161/01.STR.0000177517.01203.ebPubMedCrossRef
40.
Planas AM, Solé S, Justicia C: Expression and activation of matrix metalloproteinase-2 and -9 in rat brain after transient focal cerebral ischemia. Neurobiol Dis 2001, 8: 834–846. 10.1006/nbdi.2001.0435PubMedCrossRef
41.
Ethell IM, Ethell DW: Matrix metalloproteinases in brain development and remodeling: synaptic functions and targets. J Neurosci Res 2007, 85: 2813–2823. 10.1002/jnr.21273PubMedCrossRef
42.
Zhao BQ, Wang S, Kim HY, Storrie H, Rosen BR, Mooney DJ, Wang X, Lo EH: Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat Med 2006, 12: 441–445. 10.1038/nm1387PubMedCrossRef
Metadata
Title
Early outcome and blood-brain barrier integrity after co-administered thrombolysis and hyperbaric oxygenation in experimental stroke
Authors
Dominik Michalski
Johann Pelz
Christopher Weise
Johannes Kacza
Johannes Boltze
Jens Grosche
Manja Kamprad
Dietmar Schneider
Carsten Hobohm
Wolfgang Härtig
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Experimental & Translational Stroke Medicine / Issue 1/2011
Electronic ISSN: 2040-7378
DOI
https://doi.org/10.1186/2040-7378-3-5

Other articles of this Issue 1/2011

Experimental & Translational Stroke Medicine 1/2011 Go to the issue

Research

Gender-related differences in physiologic color space: a functional transcranial Doppler (f TCD) study

Research

The ATP-binding cassette transporters ABCB1 and ABCC1 are not regulated by hypoxia in immortalised human brain microvascular endothelial cells

Research

Treatment with the immunomodulator FTY720 does not promote spontaneous bacterial infections after experimental stroke in mice

Review

Calorie restriction and stroke

Research

The protective effects of plasma gelsolin on stroke outcome in rats

Letter to the Editor

On the importance of long-term functional assessment after stroke to improve translation from bench to bedside